MCID: SBS004
MIFTS: 46

Substance Dependence

Categories: Mental diseases

Aliases & Classifications for Substance Dependence

MalaCards integrated aliases for Substance Dependence:

Name: Substance Dependence 12 54 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:9973
NCIt 50 C35458
SNOMED-CT 67 255338002
UMLS 70 C0038580 C0439857

Summaries for Substance Dependence

Disease Ontology : 12 A substance-related disorder that involves the continued use of alcohol or other drugs despite problems related to use of the substance.

MalaCards based summary : Substance Dependence is related to drug dependence and tobacco addiction. An important gene associated with Substance Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Ethanol and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Substance dependence, also known as drug dependence, is an adaptive state that develops from repeated... more...

Related Diseases for Substance Dependence

Diseases related to Substance Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 drug dependence 32.0 SLC6A4 SLC6A3 POMC OPRM1 OPRK1 OPRD1
2 tobacco addiction 31.9 SLC6A4 SLC6A3 OPRM1 MAOA DRD3 DRD2
3 alcohol dependence 31.6 SLC6A4 SLC6A3 POMC PKNOX2 OPRM1 OPRK1
4 smoking as a quantitative trait locus 3 31.4 CHRNA5 CHRNA3
5 personality disorder 31.3 SLC6A4 SLC6A3 MAOA HTR1B DRD3 DRD2
6 depression 31.3 SLC6A4 MAOA BDNF
7 post-traumatic stress disorder 31.2 SLC6A4 POMC MAOA DRD2 CNR1 BDNF
8 antisocial personality disorder 31.2 SLC6A4 SLC6A3 MAOA HTR1B DRD2
9 substance abuse 31.1 SLC6A4 SLC6A3 POMC OPRM1 MAOA IL6
10 conduct disorder 31.1 SLC6A4 SLC6A3 POMC MAOA DRD5 DRD2
11 borderline personality disorder 31.0 SLC6A4 SLC6A3 MAOA HTR1B DRD2 BDNF
12 opiate dependence 31.0 SLC6A4 SLC6A3 POMC OPRM1 OPRK1 OPRD1
13 acute stress disorder 31.0 SLC6A4 POMC IL6 BDNF
14 bulimia nervosa 30.9 SLC6A4 MAOA HTR1B DRD2 BDNF
15 bipolar disorder 30.9 SLC6A4 SLC6A3 MAOA IL6 HTR1B DRD5
16 mental depression 30.9 SLC6A4 SLC6A3 POMC MAOA IL6 HTR1B
17 withdrawal disorder 30.8 SLC6A3 POMC OPRM1 OPRK1 CNR1
18 generalized anxiety disorder 30.8 SLC6A4 SLC6A3 MAOA DRD2 BDNF
19 heroin dependence 30.8 SLC6A4 SLC6A3 OPRM1 OPRD1 MAOA DRD2
20 cocaine dependence 30.7 SLC6A4 SLC6A3 POMC OPRM1 OPRK1 OPRD1
21 cannabis abuse 30.7 DRD2 CNR1 BDNF
22 attention deficit-hyperactivity disorder 30.7 SLC6A4 SLC6A3 OPRM1 MAOA IL6 HTR1B
23 alcohol use disorder 30.7 SLC6A4 SLC6A3 OPRM1 HTR1B DRD3 DRD2
24 major depressive disorder 30.7 SLC6A4 SLC6A3 POMC OPRM1 MAOA IL6
25 anxiety 30.6 SLC6A4 SLC6A3 POMC OPRM1 MAOA IL6
26 bipolar i disorder 30.6 SLC6A4 DRD2 BDNF
27 alexithymia 30.6 SLC6A4 IL6 DRD2
28 eating disorder 30.6 SLC6A4 SLC6A3 POMC OPRM1 DRD3 DRD2
29 social phobia 30.6 SLC6A4 MAOA DRD2 BDNF
30 mood disorder 30.6 SLC6A4 SLC6A3 POMC MAOA IL6 HTR1B
31 panic disorder 30.5 SLC6A4 SLC6A3 POMC MAOA HTR1B DRD3
32 psychotic disorder 30.5 SLC6A4 SLC6A3 OPRM1 MAOA DRD3 DRD2
33 pathological gambling 30.5 SLC6A4 SLC6A3 OPRM1 MAOA DRD5 DRD3
34 anorexia nervosa 30.5 SLC6A4 POMC MAOA CNR1 BDNF
35 neonatal abstinence syndrome 30.5 OPRM1 OPRK1 OPRD1
36 opioid addiction 30.5 OPRM1 OPRK1 OPRD1 DRD2
37 sleep disorder 30.5 SLC6A4 SLC6A3 POMC IL6 BDNF
38 polysubstance abuse 30.4 DRD3 DRD2 CNR1
39 phobic disorder 30.4 SLC6A4 SLC6A3 POMC MAOA DRD2 BDNF
40 hypochondriasis 30.4 SLC6A4 POMC BDNF
41 phobia, specific 30.4 SLC6A4 MAOA BDNF
42 chronic pain 30.3 OPRM1 CNR1
43 oppositional defiant disorder 30.3 SLC6A4 SLC6A3 MAOA HTR1B DRD5 DRD2
44 schizoaffective disorder 30.3 SLC6A4 DRD3 DRD2 CNR1 BDNF
45 melancholia 30.2 SLC6A4 POMC MAOA IL6 BDNF
46 dysthymic disorder 30.2 SLC6A4 SLC6A3 POMC MAOA IL6 BDNF
47 schizophrenia 30.2 SLC6A4 SLC6A3 POMC OPRM1 MAOA IL6
48 endogenous depression 30.1 SLC6A4 SLC6A3 POMC MAOA IL6 DRD2
49 body mass index quantitative trait locus 11 30.1 SLC6A3 POMC MAOA IL6 DRD2 CNR1
50 obsessive-compulsive disorder 29.9 SLC6A4 SLC6A3 POMC MAOA IL6 HTR1B

Graphical network of the top 20 diseases related to Substance Dependence:



Diseases related to Substance Dependence

Symptoms & Phenotypes for Substance Dependence

GenomeRNAi Phenotypes related to Substance Dependence according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.4 MAOA
2 Decreased viability GR00249-S 9.4 CHRNA3 OPRK1 SLC6A4
3 Decreased viability GR00381-A-1 9.4 ADH4 SLC6A4
4 Decreased viability GR00381-A-3 9.4 SLC6A4
5 Decreased viability GR00386-A-1 9.4 ADH1A CHRNB4 POMC
6 Decreased viability GR00402-S-2 9.4 OPRK1 OPRM1

MGI Mouse Phenotypes related to Substance Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 BDNF CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2
2 homeostasis/metabolism MP:0005376 10.21 BDNF CHRNA3 CHRNB4 CNR1 DRD2 DRD3
3 digestive/alimentary MP:0005381 10.13 BDNF CHRNA3 CHRNB4 CNR1 DRD2 DRD3
4 endocrine/exocrine gland MP:0005379 10.1 BDNF DRD2 DRD5 HTR1B IL6 OPRK1
5 integument MP:0010771 10.1 BDNF CHRNA5 CHRNB4 CNR1 DRD2 IL6
6 mortality/aging MP:0010768 10.07 BDNF CHRNA3 CHRNB4 CNR1 DRD2 DRD3
7 nervous system MP:0003631 10.06 BDNF CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2
8 adipose tissue MP:0005375 10.02 CNR1 DRD2 DRD3 HTR1B IL6 OPRM1
9 no phenotypic analysis MP:0003012 9.56 BDNF CHRNA3 CNR1 DRD2 HTR1B OPRD1
10 taste/olfaction MP:0005394 8.92 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Substance Dependence

Drugs for Substance Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
3
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
4
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
5 Neurotransmitter Agents Phase 4
6 Antidepressive Agents Phase 4
7 Psychotropic Drugs Phase 4
8 Cytochrome P-450 Enzyme Inhibitors Phase 4
9 Serotonin Uptake Inhibitors Phase 4
10 Dopamine Uptake Inhibitors Phase 4
11 Dopamine Agents Phase 4
12 Lisdexamfetamine Dimesylate Phase 4
13
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
14
Methamphetamine Approved, Illicit Phase 2 537-46-2 10836
15
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
16
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
17
Cocaine Approved, Illicit Phase 2 50-36-2 446220 5760
18
Methadone Approved Phase 2 76-99-3 4095
19
Propranolol Approved, Investigational Phase 2 525-66-6 4946
20 Narcotics Phase 2
21 Narcotic Antagonists Phase 2
22 Anti-Arrhythmia Agents Phase 2
23 Vasodilator Agents Phase 2
24 Adrenergic Antagonists Phase 2
25 Adrenergic beta-Antagonists Phase 2
26 Antihypertensive Agents Phase 2
27 Adrenergic Agents Phase 2
28
Caffeine Approved Phase 1 58-08-2 2519
29 Pharmaceutical Solutions Phase 1
30 Phosphodiesterase Inhibitors Phase 1
31 Anti-Infective Agents, Local Phase 1
32 Anti-Infective Agents Phase 1
33 Naxagolide Phase 1
34
Amphetamine Approved, Illicit, Investigational 300-62-9 5826 3007
35
Varenicline Approved, Investigational 249296-44-4 5310966
36
Dronabinol Approved, Illicit 1972-08-3 16078
37 Analgesics, Opioid
38 Opiate Alkaloids

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
2 Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence Completed NCT00573534 Phase 4 Vyvanse
3 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
4 Linkage of Alcohol Abusers to Primary Care Completed NCT00278447 Phase 3
5 A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR): A Primary Prevention Initiative Examining The Impact Of Global Risk Factor Assessment & Management On Health Care In Nova Scotia Completed NCT01620996 Phase 3
6 Distress Tolerance Treatment for Substance Users Unknown status NCT01741415 Phase 2
7 A Dose Ranging Study of Modafinil for Methamphetamine Dependence Unknown status NCT00630097 Phase 2 modafinil
8 A Phase II, Randomized, Double-Blind Pilot Trial of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) for the Treatment of Cocaine and Alcohol Dependence Completed NCT00777062 Phase 2 VIVITROL (Naltrexone extended-release injectable suspension);Placebo
9 Activating Personal Network Support in Treatment Seeking Substance Users Completed NCT03194295 Phase 2
10 Memory Reconsolidation Blockade for Treating Drug Addiction: a Feasibility Study Completed NCT01634347 Phase 2 Propranolol and memory reactivation;Placebo and memory reactivation
11 Evaluating Alternative Aftercare Models for Ex-offenders Completed NCT01586689 Phase 2
12 A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects. Withdrawn NCT00793468 Phase 2 GSK598809;Nicotine Replacement Transdermal Patch;Placebo
13 Phase 1 Study of Effects of tDCS on Tobacco Withdrawal Symptoms Completed NCT01567982 Phase 1
14 A Single-blind, Randomized, Placebo Controlled, Two-period Crossover fMRI Study to Investigate the Effects of the D3 Antagonist GSK598809 on Neural and Behavioural Responses to Food Reward and Reinforcement After a Single Oral Dose of GSK598809 in Overweight and Obese Subjects. Completed NCT01039454 Phase 1 GSK598809 Capsules;GSK598809 Placebo Capsules
15 A Placebo-controlled, Single Blind, Randomized Two Part Study Toinvestigate the Tolerability, Pharmacokinetics, and brainDopamine D3 Receptor Occupancy of Increasing Repeat Doses ofGSK618334 for up to 21 Days in Healthy Volunteers. Completed NCT01036061 Phase 1 GSK618334 Low Dose;GSK618334 PET subjects;GSK618334 Medium Dose;GSK618334 High Dose
16 A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses of GSK598809 in Smokers Completed NCT00437840 Phase 1 GSK598809;Placebo
17 A Placebo Controlled, Single Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses of GSK598809 in Healthy Male and Female Volunteers for 28 Days. Completed NCT00437632 Phase 1 GSK598809;Placebo;Caffeine
18 A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward Completed NCT00605241 Phase 1 GSK598809
19 A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses (75mg and Above) of GSK598809 in Otherwise Healthy Smokers Completed NCT00728052 Phase 1 GSK598809;Placebo
20 A Study to Investigate Potential Interactions Between GSK598809 and Ethanol in Healthy Subjects Completed NCT00887367 Phase 1 GSK598809
21 An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK618334, Using 11C-PHNO as PET Ligand. Completed NCT00814957 Phase 1 GSK618334
22 An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of a 100mg Capsule Compared to Four 25mg GSK598809 Capsules and the Effect of Food on the Pharmacokinetics of the 100mg Capsule in Healthy Male and Female Volunteers. Completed NCT00728897 Phase 1 GSK598809 new formulation;GSK598809 old formulation
23 A First Time in Human, Blinded, Randomised, Placebo-Controlled, Two-cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers Completed NCT00513279 Phase 1 GSK618334;GSK618334 matching placebo tablets
24 A Placebo-controlled, Single-blind, Cross-over, Randomised, fMRI Study Comparing Cue-induced Brain Activation Patterns After a Single Oral Dose of GSK598809 or Placebo in Abstinent Alcoholic Subjects Withdrawn NCT00908206 Phase 1 GSK598809
25 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Nexalin Electrical Brain Stimulation as an Adjunctive Therapy for Substance Dependence Unknown status NCT03540745
26 Satisfaction With Care and Quality of Life in Subjects With Substance Dependence Unknown status NCT02894476
27 Behavior Change: Reinforcement Schedule Effects Completed NCT00158197
28 Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3 Completed NCT03048552
29 Randomized Controlled Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence Completed NCT02461732
30 A Randomized Trial of Concurrent Treatment for PTSD and Substance Dependence Completed NCT01365247
31 Addressing Alcohol/HIV Consequences in Substance Dependence - Boston ARCH Cohort Completed NCT01740115
32 Stress, Distress Intolerance, and Drug Dependence Completed NCT00430482
33 Efficacy of Cognitive Bias Modification in Residential Treatment for Addiction Completed NCT03000699
34 Improving Substance Abuse Treatment Aftercare Adherence and Outcome Completed NCT00057187
35 Characterizing Alpha5 Nicotinic Receptors in Alcohol and Nicotine Dependence Completed NCT01011907 varenicline;placebo
36 Evaluation of Impulsivity on Cocaine and Crack Addicts Completed NCT01550887
37 A Randomized Double-blind Placebo-controlled Trial to Working Memory Training in Substance Abusers Completed NCT02119949
38 fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults Completed NCT01320748
39 The 9-month Follow-up Study for the Patients of Illicit Substance Use Disorder After Receiving the Different Psychosocial Intervention Recruiting NCT04426565
40 Study on the Effectiveness of "Treatment Regulation Mode" Based on Neuromodulation and Electronic Follow-up to Reduce Relapse Behavior in Patients With Substance Dependence Recruiting NCT04139148
41 Addiction and Substance Dependence in Adolescence - Neurobiological Pathomechanisms and Treatment Evaluation Recruiting NCT03444974
42 Addressing Alcohol/HIV Consequences in Substance Dependence - Boston ARCH Cohort: The 4F Study Active, not recruiting NCT03414411
43 Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial Active, not recruiting NCT03767907
44 Copy of Efficacy of a Community-based PrEP Uptake Intervention for People Who Inject Drugs in the US Northeast Not yet recruiting NCT04430257

Search NIH Clinical Center for Substance Dependence

Genetic Tests for Substance Dependence

Anatomical Context for Substance Dependence

MalaCards organs/tissues related to Substance Dependence:

40
Brain, Cortex, Prefrontal Cortex, Amygdala, Eye, Spinal Cord, Liver

Publications for Substance Dependence

Articles related to Substance Dependence:

(show top 50) (show all 2263)
# Title Authors PMID Year
1
Gender effect on association between DRD2 polymorphism and substance dependence in a Spanish sample. 61 54
19217722 2009
2
Haplotypic variants in DRD2, ANKK1, TTC12, and NCAM1 are associated with comorbid alcohol and drug dependence. 54 61
18828801 2008
3
Interaction between childhood trauma and serotonin transporter gene variation in suicide. 61 54
17356577 2007
4
CNR1 variation modulates risk for drug and alcohol dependence. 61 54
17509535 2007
5
Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. 61 54
17085484 2006
6
Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. 54 61
16387451 2006
7
Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. 61 54
16741937 2006
8
Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. 54 61
16476706 2006
9
A simple nonparametric multipoint procedure to test for linkage through mothers or fathers as well as imprinting effects in the presence of linkage. 54 61
16451620 2005
10
Combined effect of promoter polymorphisms in the dopamine D4 receptor and the serotonin transporter genes in heroin dependence. 61 54
16167465 2005
11
A genetic association study of the mu opioid receptor and severe opioid dependence. 61 54
12960749 2003
12
Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. 61 54
12815747 2003
13
No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males. 61 54
11901357 2002
14
A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. 61 54
11840318 2002
15
The D3 dopamine receptor and substance dependence. 61 54
11681590 2001
16
Family-based study of DRD2 alleles in alcohol and drug dependence. 54 61
11054774 2000
17
Antisociality, substance dependence, and the DRD5 gene: a preliminary study. 61 54
11054773 2000
18
Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. 61 54
10982041 2000
19
No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. 61 54
10023512 1999
20
Serotonin transporter protein gene polymorphism and personality measures in African American and European American subjects. 54 61
9766763 1998
21
Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF)). 54 61
9790747 1998
22
Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). 61 54
9756053 1998
23
An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: pilot study. 54 61
9583233 1998
24
Mu opioid receptor gene variants: lack of association with alcohol dependence. 54 61
9399694 1997
25
The impact of a Housing First intervention and health-related risk factors on incarceration among people with experiences of homelessness and mental illness in Canada. 61
33170496 2021
26
Identification of novel risk loci with shared effects on alcoholism, heroin, and methamphetamine dependence. 61
31462767 2021
27
Treatment resistance and prolonged length of stay among schizophrenia inpatients in forensic institutions. 61
33647704 2021
28
GABAergic polygenic risk for cocaine use disorder is negatively correlated with precuneus activity during cognitive control in African American individuals. 61
33153773 2021
29
Examining the Role of Craving, Mindfulness, and Psychological Flexibility in a Sample of Individuals with Substance Use Disorder. 61
33769196 2021
30
Resting state functional connectivity in adolescent synthetic cannabinoid users with and without attention-deficit/hyperactivity disorder. 61
33675677 2021
31
The mental health of ex-prisoners: analysis of the 2014 English National Survey of Psychiatric Morbidity. 61
33751153 2021
32
Relationship of substance dependence and time to RT-PCR negative status in patients with COVID-19 infection. 61
33571916 2021
33
Factors associated with problematic internet use among a large sample of Lebanese adolescents. 61
33781242 2021
34
Novel Risk Loci Associated With Genetic Risk for Bipolar Disorder Among Han Chinese Individuals: A Genome-Wide Association Study and Meta-analysis. 61
33263727 2021
35
Emotion dysregulation across levels of substance use. 61
33406445 2021
36
Altered neural activities during response inhibition in adults with addiction: a voxel-wise meta-analysis. 61
33612127 2021
37
Similarities in alcohol and opioid withdrawal syndromes suggest common negative reinforcement mechanisms involving the interoceptive antireward pathway. 61
33647322 2021
38
Associations between opioid dependence and sweet taste preference. 61
33527169 2021
39
Bipolar Disorder Course and Outcome Study from India (BiD-CoIN study): Sample Description & Methods. 61
33221603 2021
40
[ICD-11: changes in the diagnostic criteria of substance dependence]. 61
33591416 2021
41
Variation in provider attitudes and treatment recommendations for individuals with schizophrenia and additional marginalized identities: A mixed-method study. 61
33600201 2021
42
Dynamic networks of psychotic symptoms in adults living in precarious housing or homelessness. 61
33455593 2021
43
A voxel-wise meta-analysis of task-based functional MRI studies on impaired gain and loss processing in adults with addiction. 61
33185525 2021
44
Probing drug-evoked cortical plasticity with brain stimulation: A call for translation from animal to human medical research. 61
33276104 2021
45
Profile of Substance Misuse among Adolescent and Young Adult Gabapentinoid Users: A Register-Based Follow-up Study of Former Adolescent Psychiatric Inpatients. 61
33663338 2021
46
Safety and Feasibility of Nucleus Accumbens Surgery for Drug Addiction: A Systematic Review. 61
33460201 2021
47
Multi-environment gene interactions linked to the interplay between polysubstance dependence and suicidality. 61
33431810 2021
48
Mapping cortical and subcortical asymmetries in substance dependence: Findings from the ENIGMA Addiction Working Group. 61
33508888 2021
49
The use of telehealth to increase mental health services access and promote medication adherence in rural locations. 61
33463982 2021
50
Observations from a peculiar case of volatile substance dependence-A case report. 61
32752981 2021

Variations for Substance Dependence

Expression for Substance Dependence

Search GEO for disease gene expression data for Substance Dependence.

Pathways for Substance Dependence

Pathways related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 POMC OPRM1 OPRK1 OPRD1 IL6 HTR1B
2
Show member pathways
13.02 POMC OPRM1 OPRK1 OPRD1 HTR1B DRD5
3
Show member pathways
12.85 SLC6A4 SLC6A3 MAOA CHRNB4 CHRNA5 CHRNA3
4
Show member pathways
12.47 SLC6A3 MAOA DRD5 DRD3 DRD2 CHRNB4
6 12.1 POMC HTR1B DRD5 DRD2 BDNF
7 11.93 SLC6A4 MAOA IL6 CHRNB4 BDNF
8
Show member pathways
11.87 SLC6A3 MAOA DRD2 BDNF
9
Show member pathways
11.82 HTR1B DRD5 DRD3 DRD2
10
Show member pathways
11.71 DRD3 DRD2 CHRNA5 CHRNA3
11
Show member pathways
11.65 CHRNB4 CHRNA5 CHRNA3
12
Show member pathways
11.64 MAOA ADH4 ADH1A
13 11.61 POMC OPRM1 OPRD1 MAOA IL6
14
Show member pathways
11.32 SLC6A4 SLC6A3 MAOA
15 11.08 SLC6A4 MAOA HTR1B
16
Show member pathways
11.02 SLC6A4 SLC6A3 MAOA
17
Show member pathways
10.76 MAOA ADH4
18
Show member pathways
10.53 SLC6A4 SLC6A3 MAOA HTR1B DRD5 DRD3
19
Show member pathways
10.45 CHRNB4 CHRNA3

GO Terms for Substance Dependence

Cellular components related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.37 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 MAOA
2 plasma membrane GO:0005886 10.34 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 HTR1B
3 synapse GO:0045202 9.97 SLC6A4 OPRK1 DRD5 DRD3 DRD2 CNR1
4 axon GO:0030424 9.93 SLC6A3 OPRM1 DRD2 CNR1 BDNF
5 dendrite GO:0030425 9.91 OPRM1 OPRK1 HTR1B DRD2 CHRNA3 BDNF
6 neuron projection GO:0043005 9.86 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 CHRNB4
7 postsynaptic membrane GO:0045211 9.85 OPRD1 CHRNB4 CHRNA5 CHRNA3
8 membrane raft GO:0045121 9.85 SLC6A4 SLC6A3 OPRM1 OPRD1 CNR1
9 integral component of plasma membrane GO:0005887 9.77 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 HTR1B
10 GABA-ergic synapse GO:0098982 9.74 DRD3 DRD2 CNR1
11 axon terminus GO:0043679 9.73 OPRK1 OPRD1 DRD2
12 acetylcholine-gated channel complex GO:0005892 9.58 CHRNB4 CHRNA5 CHRNA3
13 integral component of postsynaptic membrane GO:0099055 9.55 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2
14 dopaminergic synapse GO:0098691 9.54 SLC6A3 DRD2 CHRNA5
15 spine apparatus GO:0097444 9.51 OPRM1 OPRD1
16 serotonergic synapse GO:0099154 9.48 SLC6A4 HTR1B
17 integral component of presynaptic membrane GO:0099056 9.23 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 HTR1B

Biological processes related to Substance Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.18 POMC OPRM1 OPRK1 OPRD1 HTR1B DRD5
2 cytokine-mediated signaling pathway GO:0019221 10.05 POMC OPRM1 OPRD1 MAOA IL6
3 response to drug GO:0042493 10.03 SLC6A4 SLC6A3 DRD3 DRD2
4 signal transduction GO:0007165 10 POMC OPRM1 OPRK1 OPRD1 IL6 HTR1B
5 chemical synaptic transmission GO:0007268 9.93 OPRK1 HTR1B DRD5 CHRNB4 CHRNA5 CHRNA3
6 neuropeptide signaling pathway GO:0007218 9.92 POMC OPRM1 OPRK1 OPRD1
7 regulation of membrane potential GO:0042391 9.91 CHRNB4 CHRNA5 CHRNA3
8 cellular calcium ion homeostasis GO:0006874 9.9 DRD5 DRD3 DRD2
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.89 OPRD1 IL6 BDNF
10 memory GO:0007613 9.89 SLC6A4 CNR1 BDNF
11 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.89 OPRM1 OPRD1 HTR1B CNR1
12 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.87 OPRM1 OPRK1 OPRD1
13 sensory perception of pain GO:0019233 9.86 OPRM1 OPRK1 CNR1
14 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.86 OPRM1 OPRK1 OPRD1 HTR1B
15 nervous system process GO:0050877 9.85 CHRNB4 CHRNA5 CHRNA3
16 regulation of synaptic vesicle exocytosis GO:2000300 9.84 HTR1B DRD2 CHRNA5
17 regulation of sensory perception of pain GO:0051930 9.81 OPRM1 OPRK1 OPRD1
18 regulation of dopamine secretion GO:0014059 9.8 HTR1B DRD3 DRD2
19 eating behavior GO:0042755 9.79 OPRM1 OPRK1 OPRD1
20 synaptic transmission, cholinergic GO:0007271 9.78 CHRNB4 CHRNA5 CHRNA3
21 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.77 DRD5 DRD3 DRD2
22 locomotory behavior GO:0007626 9.77 SLC6A3 OPRK1 DRD3 DRD2 CHRNA3
23 negative regulation of cytosolic calcium ion concentration GO:0051481 9.76 OPRM1 DRD3 DRD2
24 behavioral response to cocaine GO:0048148 9.75 OPRK1 DRD3 DRD2
25 G protein-coupled receptor internalization GO:0002031 9.74 HTR1B DRD3 DRD2
26 dopamine metabolic process GO:0042417 9.73 DRD3 DRD2
27 behavior GO:0007610 9.73 OPRK1 HTR1B
28 response to nicotine GO:0035094 9.73 SLC6A3 DRD2 CNR1 CHRNA5
29 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A4 SLC6A3
30 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
31 regulation of synaptic transmission, GABAergic GO:0032228 9.72 DRD2 CNR1
32 sensory perception GO:0007600 9.72 OPRM1 OPRK1
33 prepulse inhibition GO:0060134 9.72 SLC6A3 DRD3 DRD2
34 excitatory postsynaptic potential GO:0060079 9.72 OPRM1 DRD2 CHRNB4 CHRNA5 CHRNA3
35 ethanol oxidation GO:0006069 9.71 ADH4 ADH1A
36 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD3 DRD2
37 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.71 DRD5 DRD3
38 dopamine catabolic process GO:0042420 9.71 SLC6A3 MAOA
39 synaptic transmission, dopaminergic GO:0001963 9.71 DRD5 DRD3 DRD2
40 negative regulation of blood pressure GO:0045776 9.71 DRD5 DRD3 DRD2 CNR1
41 monoamine transport GO:0015844 9.7 SLC6A4 SLC6A3
42 behavioral response to ethanol GO:0048149 9.7 OPRM1 DRD2
43 adenohypophysis development GO:0021984 9.7 SLC6A3 DRD2
44 hyaloid vascular plexus regression GO:1990384 9.69 SLC6A3 DRD2
45 drinking behavior GO:0042756 9.69 HTR1B DRD2
46 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.69 HTR1B DRD3 DRD2
47 regulation of potassium ion transport GO:0043266 9.68 DRD3 DRD2
48 behavioral response to nicotine GO:0035095 9.68 CHRNA5 CHRNA3
49 alcohol metabolic process GO:0006066 9.68 ADH4 ADH1A
50 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.67 DRD3 DRD2

Molecular functions related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.48 SLC6A4 SLC6A3 POMC PKNOX2 OPRM1 OPRK1
2 G protein-coupled receptor activity GO:0004930 9.86 OPRM1 OPRK1 OPRD1 HTR1B DRD5 DRD3
3 peptide binding GO:0042277 9.73 OPRM1 OPRK1 OPRD1
4 neurotransmitter receptor activity GO:0030594 9.71 HTR1B CHRNB4 CHRNA5 CHRNA3
5 extracellular ligand-gated ion channel activity GO:0005230 9.7 CHRNB4 CHRNA5 CHRNA3
6 ligand-gated ion channel activity GO:0015276 9.69 CHRNB4 CHRNA5 CHRNA3
7 drug binding GO:0008144 9.63 SLC6A3 HTR1B CNR1
8 neuropeptide binding GO:0042923 9.61 OPRM1 OPRK1 OPRD1
9 serotonin binding GO:0051378 9.59 SLC6A4 HTR1B
10 acetylcholine binding GO:0042166 9.58 CHRNB4 CHRNA3
11 monoamine transmembrane transporter activity GO:0008504 9.58 SLC6A4 SLC6A3
12 alcohol dehydrogenase (NAD) activity GO:0004022 9.57 ADH4 ADH1A
13 alcohol dehydrogenase activity, zinc-dependent GO:0004024 9.55 ADH4 ADH1A
14 receptor serine/threonine kinase binding GO:0033612 9.54 OPRK1 OPRD1
15 acetylcholine-gated cation-selective channel activity GO:0022848 9.54 CHRNB4 CHRNA5 CHRNA3
16 acetylcholine receptor activity GO:0015464 9.5 CHRNB4 CHRNA5 CHRNA3
17 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.49 DRD3 DRD2
18 opioid receptor activity GO:0004985 9.33 OPRM1 OPRK1 OPRD1
19 dopamine binding GO:0035240 9.13 SLC6A3 DRD5 DRD2
20 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD5 DRD3 DRD2

Sources for Substance Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....